GlycoMimetics Q2 cash $58M; uproleselan Phase 3 topline by Q2 2024; GMI-1687 Phase 1a in Q3

CRESCENT BIOPHARMA, INC.

Cash $58.0M at June 30, 2023, up from $47.9M at Dec 31, 2022; R&D spend $4.1M, down 49% YoY.
Pivotal Phase 3 uproleselan R/R AML topline results expected by end of Q2 2024 after time-based analysis amendment.
FDA agreed to initial Pediatric Study Plan; NCI will sponsor Phase 1/2 uproleselan study in pediatric AML.
First pediatric patient dosed in investigator-initiated Phase 1/2 study of uproleselan with pre-transplant conditioning.
GMI-1687 (E-selectin antagonist) Phase 1a study in healthy volunteers to initiate in Q3 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRESCENT BIOPHARMA, INC. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 2, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-012816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.